Description
Selpercatinib is a selective RET kinase inhibitor used to treat RET fusion-positive colorectal cancer. This targeted therapy specifically blocks the abnormal RET protein that drives tumor growth in patients with RET gene alterations.
Mechanism of Action
Selpercatinib works by selectively inhibiting the RET kinase enzyme, blocking downstream signaling pathways that promote cancer cell proliferation and survival. This targeted approach disrupts the molecular pathway driving tumor growth in RET-altered cancers.
Side Effects
Fatigue
Diarrhea
Constipation
Nausea
Decreased appetite
Dry mouth
Hypertension
Headache
Rash
Peripheral edema
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT04320888
Phase 2
Active, not recruiting
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
United States, Australia, Puerto Rico
NCT04280081
Phase 2
Active, not recruiting
A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation
China
NCT03155620
Phase 2
Active, not recruiting
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
United States, Australia, Canada, Puerto Rico